Welcome to our dedicated page for Harte-Hanks news (Ticker: HHS), a resource for investors and traders seeking the latest updates and insights on Harte-Hanks stock.
Harte Hanks, Inc. reports news as a customer experience company serving clients through Revenue Solutions, Customer Care, and Fulfillment & Logistics Services. Company updates commonly cover quarterly and annual results, revenue trends by segment, EBITDA and adjusted EBITDA measures, cost controls, customer contract transitions, and operating initiatives such as Project Elevate.
Recurring developments also include customer care partnerships, data-driven marketing assets, healthcare marketing capabilities, leadership changes, and financing actions such as amendments to its asset-based revolving credit facility. Its Fulfillment & Logistics Services business includes printing, lettershop, mail optimization, logistics, transportation optimization, monitoring, and tracking for traditional and specialized mailings.
Harte Hanks (Nasdaq: HHS) partnered with a leading global financial services corporation to deliver over 300,000 at-home Covid-19 testing kits during the Omicron surge. Additionally, the company distributed more than 60,000 wellness kits containing hand sanitizers and PPE masks to its employees. This initiative was supported by their FDA-certified distribution center in Kansas City, allowing prompt delivery. The company emphasizes its significant investments in fulfillment facilities as a driver of growth amidst ongoing supply chain challenges.
Harte Hanks (HHS) reported a 10% revenue increase in Q4 2021, totaling $52.0 million, up from $47.1 million in Q4 2020. Diluted EPS rose to $0.20 from $0.11. Full-year revenues also improved by 10% to $194.6 million, while net income surged to $15.0 million compared to a net loss of $1.7 million in 2020. The company achieved an operating income of $7.6 million, reversing a previous loss. Cash and equivalents decreased to $15.1 million, but the company expects a $7.8 million tax refund to boost liquidity. CEO Brian Linscott emphasized sustainable profitability growth in 2022.
Harte Hanks, Inc. (Nasdaq: HHS) announced it will release its financial results for Q4 ended December 31, 2021, after the market closes on February 24, 2022. A conference call will follow at 4:30 p.m. ET to discuss the results. Interested parties can access the webcast online or via phone. The company specializes in customer experience strategies and analytics, serving clients like Bank of America and Pfizer, with over 2,500 employees in multiple regions.
Harte Hanks (Nasdaq: HHS) has secured a multi-year contract from a national healthcare organization to provide new mothers with essential products, including breast milk pumps and health-related materials. This initiative aligns with the Affordable Care Act's goal to enhance newborn nutrition. Over 100,000 breast milk kits are expected to be delivered in the first year. Harte Hanks was chosen for its comprehensive, cost-effective solutions and established relationship with the client, enabling efficient service delivery.
Harte Hanks (Nasdaq: HHS) announced the launch of an expanded healthcare practice, spearheaded by Janel Harris, an executive with extensive healthcare agency experience. The practice aims to leverage integrated services including patient insights and data analytics, enhancing client engagement in the healthcare sector. The company operates multiple distribution centers, including a new 400,000 square foot facility in Kansas City, fulfilling over 1.3 million packages annually. Harte Hanks continues to cater to major clients like GSK and Pfizer, aiming to provide comprehensive patient-centric solutions.
Harte Hanks (Nasdaq: HHS), a global customer experience company, will present at the Sidoti & Company Virtual Small-Cap Conference on January 20, 2022, at 10 a.m. ET. Management will also hold one-on-one meetings on January 19 and 20, 2022. Interested parties can access the presentation via webcast on the Harte Hanks investor relations website. For meeting requests, participants may contact their Sidoti representative or email hhs@fnkir.com.
Harte Hanks (NASDAQ: HHS) has appointed Don Aicklen as the new Senior Vice President of Sales and Marketing, returning to the company with extensive sales experience. Aicklen previously led Harte Hanks' national sales organization, contributing to significant growth, particularly in automotive and consumer durables. His past leadership at KBM Group and startups in marketing services also highlights his expertise. CEO Brian Linscott praised Aicklen's talent and strategic vision to drive growth initiatives in 2022 and beyond.
Harte Hanks, Inc. (HHS) announced a new $25 million revolving line of credit with Texas Capital Bank on Dec. 21, 2021. This credit facility aims to enhance the company's strategic position and financial flexibility, allowing for working capital, debt repayment, and investment in client offerings. CEO Brian Linscott highlighted the facility's importance for ensuring financial stability and eliminating the need for third-party guarantees, showcasing the success of their turnaround plan.
Harte Hanks, Inc. (OTCQX: HRTH) has announced its approval for listing on the Nasdaq, effective December 1, 2021, where it will trade under the symbol 'HHS'. The company has met stringent financial and corporate governance requirements. This uplisting is viewed as a significant milestone that is expected to enhance liquidity and investor access. Chairman Jack Griffin emphasized the return to a national exchange as a major progress indicator, while CEO Brian Linscott highlighted the potential to expand the institutional shareholder base and increase long-term shareholder value.
Harte Hanks (NYSE: HHS) was notified by the NYSE on July 9, 2020, about the commencement of delisting proceedings due to non-compliance with listing standards, specifically failing to maintain $50 million in stockholders' equity or market capitalization. The company plans to transition to the OTCQX Best Market, where it will trade under the symbol "HRTE." Despite the delisting, Harte Hanks asserts that its business operations will remain unaffected. The NYSE will inform about the suspension date after the review period.